Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company based in Brisbane, California, at the forefront of pioneering genomic medicine. Leveraging its advanced platform technologies across gene therapy, cell therapy, genome editing, and genome regulation, the company aims to address significant unmet medical needs while enhancing patient outcomes. With a robust pipeline that targets both genetic and acquired diseases, Sangamo is strategically positioned to be a key influencer in the rapidly evolving field of genomic therapies. Show more

Location: 501 CANAL BLVD, RICHMOND, CA, UNITED STATES, 94804, Richmond, CA, 94804, USA | Website: https://www.sangamo.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

180.2M

52 Wk Range

$0.35 - $1.40

Previous Close

$0.54

Open

$0.52

Volume

7,088,084

Day Range

$0.49 - $0.60

Enterprise Value

176M

Cash

30.53M

Avg Qtr Burn

-28.5M

Insider Ownership

2.21%

Institutional Own.

18.71%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ST-920 (isaralgagene civaparvovec) Details Fabry disease	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Giroctocogene fitelparvovec (SB-525 / PF-07055480) Details Rare diseases, Hemophilia, Rare genetic disease, Blood disorder	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX-200 Details Kidney disease, Kidney transplantation	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ST-503 Details Idiopathic small fiber neuropathy	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ST-506 Details Prion disease	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ST-400 Details Blood disorder, Beta thalessemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SB-913 Details Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BIVV003 (SAR445136) Details Sickle cell disease, Blood disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.